Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life setting.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nanni Jacopo, Azzali Irene, Papayannidis Cristina, Mulè Antonino, Audisio Ernesta, Martelli Maria Paola, Scappini Barbara, Chiusolo Patrizia, Cambò Benedetta, Candoni Anna, Lunghi Monia, Albano Francesco, Olivieri Attilio, Fracchiolla Nicola, Bernardi Massimo, Romani Claudio, Rigolin Gian Matteo, Giannini Maria Benedetta, Bocchia Monica, Todisco Elisabetta, Cilloni Daniela, Bochicchio Maria Teresa, Ottaviani Emanuela, Mattei Agnese, Zamagni Federica, Valli Irene, Volpi Roberta, Marconi Giovanni, Petracci Elisabetta, FLAM Collaborative Group, Martinelli Giovanni
Аннотация
METHODS: Clinical data are reported from 394 ND patients with FLT3-mutated AML enrolled in the retrospective observational Italian Cohort Study on FLT3-mutated patients with AML and treated with an upfront intensive regimen with (FLT3i group, n = 92) or without (CT group, n = 302) the addition of a FLT3i.
RESULTS: With a median follow-up time of 34.5 months, an effectiveness benefit obtained by FLT3i incorporation both in terms of overall survival (median, 34.9 in the FLT3i vs 12.7 months in the CT group, p < .01) and relapse-free survival (median, 18.9 in the FLT3i vs 7.6 months in the CT group, p = .01) was documented, with a higher composite complete remission rate (75.4% in the FLT3i vs 62.4% in the CT group, p = .052). FLT3i benefit seemed to be independent from the transplant rate.
CONCLUSIONS: In conclusion, the benefit of FLT3i addition to upfront intensive treatment in newly diagnosed FLT3-mutated AML patients was confirmed in a large, real-life cohort study.